HCA Midwest Health brings cutting-edge clinical trials to Kansas City
KANSAS CITY — HCA Midwest Health is bringing new, cutting-edge clinical trials to its Kansas City hospitals for the first time — a move that’s imperative to the advancement of cancer research, said Dr. Howard Burris, president of clinical operations and chief medical officer for Sarah Cannon HCA Midwest Health told the Kansas City Business Journal.
The health system has partnered up with Sarah Cannon Research Institute to give patients in Kansas City more access to the the latest clinic trials and therapies. The strategic partnership will build on HCA’s already existing clinical research program by providing a new pipeline of clinical trial options and new drug therapies, Research Medical Center COO Johnathon Myers said. During the past decade, Sarah Cannon has been a clinical trial leader in approximately 80 percent of approved cancer therapies.
Burris said the Kansas City metro is a critical location for new trials because of its health culture and dedicated, engaged physicians.
Check for Research Medical Center jobs here.
Read more about this story in the Kansas City Business Journal by Dora Grote